Source: Annual Congress 2005 - Scientific year in review
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Maclean (Glasgow, United Kingdom). Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension. Annual Congress 2005 - Scientific year in review

Member's Comments

No comment yet.

Related content which might interest you: In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 The pathobiology and genetics of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Expression of fetal genes in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003 Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Role of anti-proliferative therapy in PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Chronic thromboembolic pulmonary hypertension: animal models Source: Eur Respir J 2013; 41: 1200-1206 Year: 2013 New insights in pulmonary vascular biology and pathophysiology Source: Annual Congress 2006 - Physiological year in review Year: 2006